Fibulin-3 in plasma and pleural effusion as a biomarker of mesothelioma

1. Asciak R, George V, Rahman NM. Update on biology and management of mesothelioma. Eur Respir Rev 2021; 30: 200226. doi: 10.1183/16000617.0226-2020 Asciak R George V Rahman NM. Update on biology and management of mesothelioma . Eur Respir Rev 2021 ; 30 : 200226 . 10.1183/16000617.0226-2020 Open DOISearch in Google Scholar

2. Mlika M, Lamzirbi O, Limam M, Mejri N, Ben Saad S, Chaouch N, et al. [Clinical and pathological profile of the pleural malignant mesothelioma: a retrospective study about 30 cases]. [French]. Rev Pneumol Clin 2018; 74: 427-35. doi: 10.1016/j.pneumo.2018.06.004 Mlika M Lamzirbi O Limam M Mejri N Ben Saad S Chaouch N [Clinical and pathological profile of the pleural malignant mesothelioma: a retrospective study about 30 cases]. [French] . Rev Pneumol Clin 2018 ; 74 : 427 - 35 . 10.1016/j.pneumo.2018.06.004 Open DOISearch in Google Scholar

3. Franko A; Kotnik N; Goricar K; Kovac V; Dodic-Fikfak M; Dolzan V. The influence of genetic variability on the risk of developing malignant mesothelioma. Radiol Oncol 2018; 52: 105-11. doi: 10.2478/raon-2018-0004 Franko A Kotnik N Goricar K Kovac V Dodic-Fikfak M Dolzan V. The influence of genetic variability on the risk of developing malignant mesothelioma . Radiol Oncol 2018 ; 52 : 105 - 11 . 10.2478/raon-2018-0004 Open DOISearch in Google Scholar

4. Wen W, Xu D, Piao Y, Li X. Prognostic value of maximum standard uptake value, metabolic tumour volume, and total lesion glycolysis of 18F-FDG PET/CT in patients with malignant pleural mesothelioma: a systematic review and meta-analysis. Cancer Cell Int 2022 3; 22: 60. doi: 10.1186/s12935-022-02482-5 Wen W Xu D Piao Y Li X. Prognostic value of maximum standard uptake value, metabolic tumour volume, and total lesion glycolysis of 18F-FDG PET/CT in patients with malignant pleural mesothelioma: a systematic review and meta-analysis . Cancer Cell Int 2022 3 ; 22 : 60 . 10.1186/s12935-022-02482-5 Open DOISearch in Google Scholar

5. Kovac V; Zwitter M; Zagar T. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: population-based survey of 444 patients. Radiol Oncol 2012; 46: 136-144. doi: 10.2478/v10019-012-0032-0 Kovac V Zwitter M Zagar T. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: population-based survey of 444 patients . Radiol Oncol 2012 ; 46 : 136 - 144 . 10.2478/v10019-012-0032-0 Open DOISearch in Google Scholar

6. Royal College of Physicians (RCP). National Mesothelioma Audit Report 2020 (Audit Period 2016–18). [internet]. London, UK: RCP; 2020. [cited 2023 May]. Available at: www.rcplondon.ac.uk/projects/outputs/nationalmesothelioma-audit-report-2020-audit-period-2016-18 Royal College of Physicians (RCP) National Mesothelioma Audit Report 2020 (Audit Period 2016–18) . [internet]. London, UK : RCP ; 2020 . [cited 2023 May ]. Available at: www.rcplondon.ac.uk/projects/outputs/national-mesothelioma-audit-report-2020-audit-period-2016-18 Search in Google Scholar

7. Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo. org. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol 2022; 33: 129-42. doi: 10.1016/j.annonc.2021.11.005 Popat S Baas P Faivre-Finn C Girard N Nicholson AG Nowak AK ESMO Guidelines Committee Electronic address: clinicalguidelines@esmo. org. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ . Ann Oncol 2022 ; 33 : 129 - 42 . 10.1016/j.annonc.2021.11.005 Open DOISearch in Google Scholar

8. Nakajima EC, Vellanki PJ, Larkins E, Chatterjee S, Mishra-Kalyani PS, Bi Y, Qosa H, et al. FDA Approval Summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma. Clin Cancer Res 2022; 28: 446-51. doi: 10.1158/1078-0432.CCR-21-1466 Nakajima EC Vellanki PJ Larkins E Chatterjee S Mishra-Kalyani PS Bi Y Qosa H FDA Approval Summary: nivolumab in combination with ipili-mumab for the treatment of unresectable malignant pleural mesothelioma . Clin Cancer Res 2022 ; 28 : 446 - 51 . 10.1158/1078-0432.CCR-21-1466 Open DOISearch in Google Scholar

9. Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021; 397: 375-86. doi: 10.1016/S0140-6736(20)32714-8. Erratum in: Lancet 2021 20; 397: 670. doi: 10.1016/S0140-6736(21)00369-X Baas P Scherpereel A Nowak AK Fujimoto N Peters S Tsao AS First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial . Lancet 2021 ; 397 : 375 - 86 . 10.1016/S0140-6736(20)32714-8 . Erratum in: Lancet 2021 20; 397: 670. 10.1016/S0140-6736(21)00369-X Open DOISearch in Google Scholar

10. Woolhouse I, Bishop L, Darlison L, De Fonseka D, Edey A, Edwards J, et al. British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. Thorax 2018; 73(Suppl 1): i1-30. doi: 10.1136/thoraxjnl-2017-211321 Woolhouse I Bishop L Darlison L De Fonseka D Edey A Edwards J British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma . Thorax 2018 ; 73 ( Suppl 1 ): i1 - 30 . 10.1136/thoraxjnl-2017-211321 Open DOISearch in Google Scholar

11. Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, et al. ERS/ESTS/EACTS/ESTRO Guidelines for the management of malignant pleural mesothelioma. Eur Respir J 2020; 55: 1900953. doi: 10.1183/13993003.00953-2019 Scherpereel A Opitz I Berghmans T Psallidas I Glatzer M Rigau D ERS/ESTS/EACTS/ESTRO Guidelines for the management of malignant pleural mesothelioma . Eur Respir J 2020 ; 55 : 1900953 . 10.1183/13993003.00953-2019 Open DOISearch in Google Scholar

12. Pesch B, Brüning T, Johnen G, Casjens S, Bonberg N, Taeger D, et al. Biomarker research with prospective study designs for the early detection of cancer. Biochim Biophys Acta 2014; 1844: 874-83. doi: 10.1016/j.bbapap.2013.12.007 Pesch B Brüning T Johnen G Casjens S Bonberg N Taeger D Biomarker research with prospective study designs for the early detection of cancer . Biochim Biophys Acta 2014 ; 1844 : 874 - 83 . 10.1016/j.bbapap.2013.12.007 Open DOISearch in Google Scholar

13. Kaya H, Demir M, Taylan M, Sezgi C, Tanrikulu AC, Yilmaz S, et al. Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma. Asian Pac J Cancer Prev 2015; 16: 1403-7. doi: 10.7314/apjcp.2015.16.4.1403 Kaya H Demir M Taylan M Sezgi C Tanrikulu AC Yilmaz S Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma . Asian Pac J Cancer Prev 2015 ; 16 : 1403 - 7 . 10.7314/apjcp.2015.16.4.1403 Open DOISearch in Google Scholar

14. Livingstone I, Uversky VN, Furniss D, Wiberg A. The pathophysiological significance of fibulin-3. Biomolecules 2020; 10: 1294. doi: 10.3390/biom10091294 Livingstone I Uversky VN Furniss D Wiberg A. The pathophysiological significance of fibulin-3 . Biomolecules 2020 ; 10 : 1294 . 10.3390/biom10091294 Open DOISearch in Google Scholar

15. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 2012; 367: 1417-27. doi: 10.1056/NEJMoa1115050. Erratum in: N Engl J Med 2012; 367: 1768. doi: 10.1056/NEJMc1213514 Pass HI Levin SM Harbut MR Melamed J Chiriboga L Donington J Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma . N Engl J Med 2012 ; 367 : 1417 - 27 . 10.1056/NEJMoa1115050 . Erratum in: N Engl J Med 2012; 367: 1768. 10.1056/NEJMc1213514 Open DOISearch in Google Scholar

16. Battolla E, Canessa PA, Ferro P, Franceschini MC, Fontana V, Dessanti P, et al. Comparison of the diagnostic performance of fibulin-3 and mesothelin in patients with pleural effusions from malignant mesothelioma. Anticancer Res 2017; 37: 1387-91. doi: 10.21873/anticanres.11460 Battolla E Canessa PA Ferro P Franceschini MC Fontana V Dessanti P Comparison of the diagnostic performance of fibulin-3 and mesothelin in patients with pleural effusions from malignant mesothelioma . Anticancer Res 2017 ; 37 : 1387 - 91 . 10.21873/anticanres.11460 Open DOISearch in Google Scholar

17. Schillebeeckx E, van Meerbeeck JP, Lamote K. Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis. Eur Respir Rev 2021; 30: 210057. doi: 10.1183/16000617.00572021 Schillebeeckx E van Meerbeeck JP Lamote K. Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis . Eur Respir Rev 2021 ; 30 : 210057 . 10.1183/16000617.00572021 Open DOISearch in Google Scholar

18. Ledda C, Senia P, Rapisarda V. Biomarkers for early diagnosis and prognosis of malignant pleural mesothelioma: the quest goes on. Cancers 2018; 10: 203. doi: 10.3390/cancers10060203 Ledda C Senia P Rapisarda V. Biomarkers for early diagnosis and prognosis of malignant pleural mesothelioma: the quest goes on . Cancers 2018 ; 10 : 203 . 10.3390/cancers10060203 Open DOISearch in Google Scholar

19. Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, et al. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Thorax 2014; 69: 895-902. doi: 10.1136/thoraxjnl-2014-205205 Creaney J Dick IM Meniawy TM Leong SL Leon JS Demelker Y Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma . Thorax 2014 ; 69 : 895 - 902 . 10.1136/thoraxjnl-2014-205205 Open DOISearch in Google Scholar

20. Sorino C, Mondoni M, Marchetti G, Agati S, Inchingolo R, Mei F, et al. Pleural mesothelioma: advances in blood and pleural biomarkers. J Clin Med 2023; 12: 7006. doi: 10.3390/jcm12227006 Sorino C Mondoni M Marchetti G Agati S Inchingolo R Mei F Pleural mesothelioma: advances in blood and pleural biomarkers . J Clin Med 2023 ; 12 : 7006 . 10.3390/jcm12227006 Open DOISearch in Google Scholar

21. Kirschner MB, Pulford E, Hoda MA, Rozsas A, Griggs K, Cheng YY, et al. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. Br J Cancer 2015; 113: 963-9. doi: 10.1038/bjc.2015.286 Kirschner MB Pulford E Hoda MA Rozsas A Griggs K Cheng YY Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis . Br J Cancer 2015 ; 113 : 963 - 9 . 10.1038/bjc.2015.286 Open DOISearch in Google Scholar

22. Tsim S, Alexander L, Kelly C, Shaw A, Hinsley S, Clark S, et al. Serum proteomics and plasma fibulin-3 in differentiation of mesothelioma from asbestos-exposed controls and patients with other pleural diseases. J Thorac Oncol 2021; 16: 1705-17. doi: 10.1016/j.jtho.2021.05.018 Tsim S Alexander L Kelly C Shaw A Hinsley S Clark S Serum proteomics and plasma fibulin-3 in differentiation of mesothelioma from asbestos-exposed controls and patients with other pleural diseases . J Thorac Oncol 2021 ; 16 : 1705 - 17 . 10.1016/j.jtho.2021.05.018 Open DOISearch in Google Scholar

23. Pei D, Li Y, Liu X, Yan S, Guo X, Xu X, et al. Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: evidence from a meta-analysis. Oncotarget 2017; 8: 13030-8. doi: 10.18632/on-cotarget.14712. Erratum in: Oncotarget 2018; 9: 21628. doi: 10.18632/oncotarget.25301 Pei D Li Y Liu X Yan S Guo X Xu X Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: evidence from a meta-analysis . Oncotarget 2017 ; 8 : 13030 - 8 . 10.18632/on-cotarget.14712 . Erratum in: Oncotarget 2018; 9: 21628. 10.18632/oncotarget.25301 Open DOISearch in Google Scholar

24. Napolitano A, Antoine DJ, Pellegrini L, Baumann F, Pagano I, Pastorino S, et al. HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients. Clin Cancer Res 2016; 22: 3087-96. doi: 10.1158/1078-0432.CCR-15-1130 Napolitano A Antoine DJ Pellegrini L Baumann F Pagano I Pastorino S HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients . Clin Cancer Res 2016 ; 22 : 3087 - 96 . 10.1158/1078-0432.CCR-15-1130 Open DOISearch in Google Scholar

25. Arnold DT, De Fonseka D, Hamilton FW, Rahman NM, Maskell NA. Prognostication and monitoring of mesothelioma using biomarkers: a systematic review. Br J Cancer 2017; 116: 731-41. doi: 10.1038/bjc.2017.22 Arnold DT De Fonseka D Hamilton FW Rahman NM Maskell NA. Prognostication and monitoring of mesothelioma using biomarkers: a systematic review . Br J Cancer 2017 ; 116 : 731 - 41 . 10.1038/bjc.2017.22 Open DOISearch in Google Scholar

26. Katz SI, Roshkovan L, Berger I, Friedberg JS, Alley EW, Simone CB 2nd, et al. Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial. Lung Cancer 2021; 154: 5-12. doi: 10.1016/j.lungcan.2021.01.011 Katz SI Roshkovan L Berger I Friedberg JS Alley EW Simone CB 2nd Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial . Lung Cancer 2021 ; 154 : 5 - 12 . 10.1016/j.lungcan.2021.01.011 Open DOISearch in Google Scholar

27. Roshini A, Goparaju C, Kundu S, Nandhu MS, Longo SL, Longo JA, et al. The extracellular matrix protein fibulin-3/EFEMP1 promotes pleural mesothelioma growth by activation of PI3K/Akt signaling. Front Oncol 2022; 12: 1014749. doi: 10.3389/fonc.2022.1014749 Roshini A Goparaju C Kundu S Nandhu MS Longo SL Longo JA The extracellular matrix protein fibulin-3/EFEMP1 promotes pleural mesothelioma growth by activation of PI3K/Akt signaling . Front Oncol 2022 ; 12 : 1014749 . 10.3389/fonc.2022.1014749 Open DOISearch in Google Scholar

28. Kovac V, Dodic-Fikfak M, Arneric N, Dolzan V, Franko A. Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma. Radiol Oncol 2015; 49: 279-85. doi: 10.1515/raon-2015-0019 Kovac V Dodic-Fikfak M Arneric N Dolzan V Franko A. Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma . Radiol Oncol 2015 ; 49 : 279 - 85 . 10.1515/raon-2015-0019 Open DOISearch in Google Scholar

29. Jiang Z, Ying S, Shen W, He X, Chen J, Xia H, et al. Plasma fibulin-3 as a potential biomarker for patients with asbestos-related diseases in the Han population. Dis Markers 2017; 2017: 1725354. doi: 10.1155/2017/1725354 Jiang Z Ying S Shen W He X Chen J Xia H Plasma fibulin-3 as a potential biomarker for patients with asbestos-related diseases in the Han population . Dis Markers 2017 ; 2017 : 1725354 . 10.1155/2017/1725354 Open DOISearch in Google Scholar

30. Rapisarda V, Caltabiano R, Musumeci G, Castrogiovanni P, Ferrante M, Ledda C, et al. Analysis of fibulin-3 after exposure to asbestos-like fibers. Environ Res 2017; 156: 381-7. doi: 10.1016/j.envres.2017.03.055 Rapisarda V Caltabiano R Musumeci G Castrogiovanni P Ferrante M Ledda C Analysis of fibulin-3 after exposure to asbestos-like fibers . Environ Res 2017 ; 156 : 381 - 7 . 10.1016/j.envres.2017.03.055 Open DOISearch in Google Scholar

31. Musk AW, de Klerk N, Reid A, Hui J, Franklin P, Brims F. Asbestos-related diseases. Int J Tuberc Lung Dis 2020; 24: 562-7. doi: 10.5588/ijtld.19.0645 Musk AW de Klerk N Reid A Hui J Franklin P Brims F. Asbestos-related diseases . Int J Tuberc Lung Dis 2020 ; 24 : 562 - 7 . 10.5588/ijtld.19.0645 Open DOISearch in Google Scholar

32. Argraves WS, Greene LM, Cooley MA, Gallagher WM. Fibulins: physiological and disease perspectives. EMBO Rep 2003; 4: 1127-31. doi: 10.1038/sj.embor.7400033 Argraves WS Greene LM Cooley MA Gallagher WM. Fibulins: physiological and disease perspectives . EMBO Rep 2003 ; 4 : 1127 - 31 . 10.1038/sj.embor.7400033 Open DOISearch in Google Scholar

33. Giltay R, Timpl R, Kostka G. Sequence, recombinant expression and tissue localization of two novel extracellular matrix proteins, fibulin-3 and fibulin-4. Matrix Biol 1999; 18: 469-80. doi: 10.1016/s0945-053x(99)00038-4 Giltay R Timpl R Kostka G. Sequence, recombinant expression and tissue localization of two novel extracellular matrix proteins, fibulin-3 and fibulin-4 . Matrix Biol 1999 ; 18 : 469 - 80 . 10.1016/s0945-053x(99)00038-4 Open DOISearch in Google Scholar

34. Tsuda T. Extracellular interactions between fibulins and transforming growth factor (TGF)-β in physiological and pathological conditions. Int J Mol Sci 2018; 19: 2787. doi: 10.3390/ijms19092787 Tsuda T. Extracellular interactions between fibulins and transforming growth factor (TGF)-β in physiological and pathological conditions . Int J Mol Sci 2018 ; 19 : 2787 . 10.3390/ijms19092787 Open DOISearch in Google Scholar

35. Odisio EG, Marom EM, Shroff GS, Wu CC, Benveniste APA, Truong MT, et al. Malignant pleural mesothelioma: diagnosis, staging, pitfalls and follow-up. Semin Ultrasound CT MR 2017; 38: 559-70. doi: 10.1053/j.sult.2017.07.006 Odisio EG Marom EM Shroff GS Wu CC Benveniste APA Truong MT Malignant pleural mesothelioma: diagnosis, staging, pitfalls and follow-up . Semin Ultrasound CT MR 2017 ; 38 : 559 - 70 . 10.1053/j.sult.2017.07.006 Open DOISearch in Google Scholar

36. Lu Z, Zhang W, Huang K, Zhu M, Gu X, Wei D, et al. Systematic review, meta-analysis and bioinformatic analysis of biomarkers for prognosis of malignant pleural mesothelioma. Diagnostics 2022; 2: 2210. doi: 10.3390/diagnostics12092210 Lu Z Zhang W Huang K Zhu M Gu X Wei D Systematic review, meta-analysis and bioinformatic analysis of biomarkers for prognosis of malignant pleural mesothelioma . Diagnostics 2022 ; 2 : 2210 . 10.3390/diagnostics12092210 Open DOISearch in Google Scholar